Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF 87 3-Year EBITDA Growth Rate is 16.30% as of Dec. 2025, which is at its 10-year median of 16.30. GuruFocus rates CLVLF with a GF Scoreâ„¢ of 87/100 and a GF Valueâ„¢ of $12.49 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 51.58% on this metric.
During the past 12 months, Clinuvel Pharmaceuticals's average EBITDA Per Share Growth Rate was -20.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 31.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Clinuvel Pharmaceuticals was 52.70% per year. The lowest was -61.40% per year. And the median was 16.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Clinuvel Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
CLVLF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.30% mean?
Clinuvel Pharmaceuticals (CLVLF) has a 3-Year EBITDA Growth Rate of 16.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clinuvel Pharmaceuticals and its competitors. This is near median its historical median of 16.30. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #550 out of 1136 companies in the Biotechnology industry, placing it in the top 48.4%.
Is Clinuvel Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Clinuvel Pharmaceuticals' current 3-Year EBITDA Growth Rate of 16.30% is near median its 10-year median of 16.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Clinuvel Pharmaceuticals' value of 16.30% is 9.8% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #550 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Scoreâ„¢ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #550 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Clinuvel Pharmaceuticals' value of 16.30% is 9.8% above this benchmark. While the company's 10-year median is 16.30 vs. the industry median of 14.85, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current 3-Year EBITDA Growth Rate of 16.30% is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current 3-Year EBITDA Growth Rate is 16.30%, which is near median its own 10-year median of 16.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.49, compared to a current price of $6.37 — trading 49% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.30%, which is near median its 10-year median of 16.30 and 9.8% above the Biotechnology industry median of 14.85. Clinuvel Pharmaceuticals' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current 3-Year EBITDA Growth Rate is 16.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.37 is trading 49% below its estimated GF Value™ of $12.49.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
3-Year EBITDA Growth Rate: 16.30% (near median its 10-year median of 16.30)
GF Value™: $12.49 vs. price of $6.37 (49% below fair value)
Industry Position: 9.8% above the Biotechnology median (#550 of 1136)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
87GF Score
Get the complete analysis for CLVLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
